Basit öğe kaydını göster

dc.contributor.authorRahman, A.
dc.contributor.authorArtim-Esen, Bahar
dc.contributor.authorGiles, I.
dc.contributor.authorMcDonnell, T.
dc.contributor.authorAlbay, A.
dc.contributor.authorPERICLEOUS, Charis
dc.contributor.authorWincup, C.
dc.date.accessioned2021-03-02T23:01:25Z
dc.date.available2021-03-02T23:01:25Z
dc.date.issued2019
dc.identifier.citationAlbay A., Artim-Esen B., PERICLEOUS C., Wincup C., Giles I., Rahman A., McDonnell T., "Domain I of beta 2GPI is capable of blocking serum IgA antiphospholipid antibodies binding in vitro: an effect enhanced by PEGylation", LUPUS, cilt.28, sa.7, ss.893-897, 2019
dc.identifier.issn0961-2033
dc.identifier.otherav_0ffcd72b-4f12-4a05-86df-fe9ac144ea80
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/16273
dc.identifier.urihttps://doi.org/10.1177/0961203319851571
dc.description.abstractObjectives This study aims to inhibit antiphospholipid syndrome (APS) serum derived IgA anti-beta-2-glycoprotein I (a beta 2GPI) binding using Domain I (DI). Methods Serum from 13 APS patients was tested for IgA a beta 2GPI and Anti-Domain I. Whole IgA was purified by peptide M affinity chromatography from positive serum samples. Serum was tested for IgA a beta 2GPI binding in the presence and absence of either DI or of two biochemically modified variants containing either 20 kDa of poly(ethylene glycol) (PEG) or 40 kDa of PEG. Results Significant inhibition with DI was possible with average inhibition of 23% (N = 13). Further inhibitions using 20 kDa PEG-DI and 40 kDa PEG-DI variants showed significant inhibition (p = 0.0001) with both the 40 kDa PEG-DI and 20 kDa PEG-DI variants showing increased inhibition compared with DI alone (p = 0.0001 and p = 0.001, n = 10). Conclusions Inhibition of IgA a beta 2GPI by DI is possible and can be enhanced by biochemical modification in a subset of patients.
dc.language.isoeng
dc.subjectSağlık Bilimleri
dc.subjectİmmünoloji ve Romatoloji
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.subjectTıp
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectROMATOLOJİ
dc.titleDomain I of beta 2GPI is capable of blocking serum IgA antiphospholipid antibodies binding in vitro: an effect enhanced by PEGylation
dc.typeMakale
dc.relation.journalLUPUS
dc.contributor.department, ,
dc.identifier.volume28
dc.identifier.issue7
dc.identifier.startpage893
dc.identifier.endpage897
dc.contributor.firstauthorID71914


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster